Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Seres Plunges on Microbiome Drug Fail, Execs Profit on Insider Sales

Seres Plunges on Microbiome Drug Fail, Execs Profit on Insider Sales

The negative Seres study results from Seres are a setback for companies trying to harness the power of bacteria to treat diseases.

Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs

Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Celgene Second-Quarter Earnings Yield No Surprises, Small Guidance Bump

Celgene Second-Quarter Earnings Yield No Surprises, Small Guidance Bump

Celgene posted second-quarter earnings which exceeded analyst consensus expectations by a small margin but enough to raise guidance for the remainder of the year.

Biomarin Hemophilia Gene Therapy Advances on Strong Study Results

Biomarin Hemophilia Gene Therapy Advances on Strong Study Results

BMN 270 is one of the most important drugs in Biomarin's research pipeline and key driver of future revenue and earnings.

Anavex Alzheimer's Drug Plays Losing Game Against Placebo Effect

Anavex Alzheimer's Drug Plays Losing Game Against Placebo Effect

A small group of Alzheimer's patients treated with Anavex 2-73 are exhibiting signs of memory loss, faltering cognition and inability to take care of themselves over time.